Asahi Life Asset Management Co., Ltd. Vertex Pharmaceuticals Inc Transaction History

Asahi Life Asset Management Co., Ltd.

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	BUY	$407.69 - $446.08 $228,306 - $249,804	560 New	560 $234,000
Q3 2023 Nov 02, 2023	SELL	$338.18 - $362.46 $299,289 - $320,777	-885 Reduced 61.46%	555 $192,000
Q2 2023 Jul 21, 2023	SELL	$314.42 - $351.91 $20,437 - $22,874	-65 Reduced 4.32%	1,440 $506,000
Q1 2023 May 01, 2023	BUY	$283.23 - $323.1 $426,261 - $486,265	1,505 New	1,505 $474,000
Q2 2022 Aug 02, 2022	SELL	$234.96 - $292.55 $66,963 - $83,376	-285 Reduced 16.38%	1,455 $410,000
Q1 2022 May 11, 2022	SELL	$221.42 - $260.97 $198,170 - $233,568	-895 Reduced 33.97%	1,740 $454,000
Q4 2021 Feb 02, 2022	BUY	$177.01 - $223.45 $26,551 - $33,517	150 Added 6.04%	2,635 $579,000
Q3 2021 Oct 29, 2021	SELL	$181.39 - $202.99 $14,511 - $16,239	-80 Reduced 3.12%	2,485 $451,000
Q2 2021 Aug 10, 2021	BUY	$187.49 - $221.1 $74,996 - $88,440	400 Added 18.48%	2,565 $517,000
Q1 2021 May 07, 2021	SELL	$207.02 - $241.31 $72,457 - $84,458	-350 Reduced 13.92%	2,165 $465,000
Q4 2020 Feb 12, 2021	BUY	$207.01 - $276.09 $98,329 - $131,142	475 Added 23.28%	2,515 $594,000
Q3 2020 Nov 02, 2020	BUY	$255.65 - $303.1 $521,526 - $618,324	2,040 New	2,040 $555,000
Q4 2019 Feb 13, 2020	SELL	$166.71 - $223.91 $266,736 - $358,256	-1,600 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$166.23 - $187.09 $265,968 - $299,344	1,600 New	1,600 $271,000
Q1 2019 May 07, 2019	SELL	$163.73 - $194.7 $581,241 - $691,185	-3,550 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $539,280 - $682,345	3,550 New	3,550 $588,000

1,716

225M

1.19M

1.56M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Asahi Life Asset Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on Asahi Life Asset Management Co., Ltd. with notifications on news.